Bank of New York Mellon
RAPP

Bank of New York Mellon’s Rapport Therapeutics RAPP Stock Holding History

Bank of New York Mellon’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.43M Buy
82,222
+9,903
+14% +$364K ﹤0.01% 2661
2026
Q1 		$2.26M Sell
72,319
-1,762
-2% -$49.6K ﹤0.01% 2740
2025
Q4 		$2.25M Buy
74,081
+26,659
+56% +$738K ﹤0.01% 2760
2025
Q3 		$1.41M Buy
47,422
+7,318
+18% +$131K ﹤0.01% 3005
2025
Q2 		$456K Buy
40,104
+4,622
+13% +$49K ﹤0.01% 3556
2025
Q1 		$356K Buy
35,482
+15,514
+78% +$201K ﹤0.01% 3627
2024
Q4 		$354K Sell
19,968
-2
-0% -$44 ﹤0.01% 3697
2024
Q3 		$409K Buy
+19,970
New +$429K ﹤0.01% 3616

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
TGV
TRV GP VI Boston, Massachusetts $232M AUM 247.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Bank of New York Mellon's RAPP Position: Q2 2026 in Review

Bank of New York Mellon increased its Rapport Therapeutics (RAPP) stake by 14% in Q2 2026, buying an estimated $364K and bringing the position to 82,222 shares worth $3.43M. The position accounts for ﹤0.01% of the portfolio, ranked #2661.

Bank of New York Mellon first reported a position in RAPP in Q3 2024 and has held it in 8 quarters since. 56 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Bank of New York Mellon held 82,222 shares of Rapport Therapeutics worth $3.43M as of Q2 2026.
  • Bank of New York Mellon bought 9,903 Rapport Therapeutics shares in Q2 2026, an estimated $364K.
  • Rapport Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2661 holding.
  • Bank of New York Mellon first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 56 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.